LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Phase 1, randomised trial of LY4057996 in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration up to 47 Weeks. Started May 2025; status: recruiting.